The impact of national centralized drug procurement policy on firm performance: Evidence from Chinese pharmaceutical firms
Authors:
- Huan HeHHHuan He
- Yuanzhu ZhanYZYuanzhu Zhan
- Baofeng HuoBHBaofeng Huo
- Yufeng ZhangYZYufeng Zhang
- Xiaojie ShiXSXiaojie Shi
- 31 May 2025
- journal article
- Published by Elsevier in Transportation Research Part E: Logistics and Transportation Review
- Vol. 200
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (72091214, 71821002)
This publication has 90 references indexed in Scilit:
- The effect of customer and supplier concentrations on firm resilience during the COVID‐19 pandemic: Resource dependence and power balancingJournal of Operations Management, 2023
- The impact of governmental COVID‐19 measures on manufacturers' stock market valuations: The role of labor intensity and operational slackJournal of Operations Management, 2022
- Do political ties facilitate operational efficiency? A contingent political embeddedness perspectiveJournal of Operations Management, 2022
- When one door closes, another door opens … for some: Evidence from the post‐TRIPS Indian pharmaceutical industryStrategic Management Journal, 2020
- Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASEPharmacology Research & Perspectives, 2019
- Rent appropriation of knowledge‐based assets and firm performance when institutions are weak: A study of Chinese publicly listed firmsStrategic Management Journal, 2016
- Collaborative procurement among competing buyersNaval Research Logistics (NRL), 2008
- Export and domestic sales: their interrelationship and determinantsStrategic Management Journal, 2005
- Do formal contracts and relational governance function as substitutes or complements?Strategic Management Journal, 2002
- CEO duality and organizational performance: A longitudinal analysisStrategic Management Journal, 1991